Discriminant power of combined cerebrospinal fluid τ protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease1Preliminary parts of this study have been presented in abstract form at the 6th International Conference on Alzheimer's Disease and Related Disorders, July 18–23, 1998, Amsterdam, The Netherlands and at the 28th Annual Meeting of the Society for Neuroscience, November 7–12, 1998, Los Angeles, CA, USA.1
Authors:
- Harald HampelHHHarald Hampel
- Matthias RiemenschneiderMRMatthias Riemenschneider
- Ruth DukoffRDRuth Dukoff
- 1 March 1999
- journal article
- Published by Elsevier in Brain Research
- Vol. 823 (1-2) , 104-112
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in JapanAnnals of Neurology, 1998
- gp130, a Shared Signal Transducing Receptor Component for Hematopoietic and Neuropoietic CytokinesJournal of Neurochemistry, 1996
- Increased levels of τ protein in cerebrospinal fluid of patients with alzheimer's disease—correlation with degree of cognitive impairmentAnnals of Neurology, 1995
- Differential shedding of the two subunits of the interleukin‐6 receptorFEBS Letters, 1993
- Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptorBiochemical and Biophysical Research Communications, 1992
- Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease corticesFEBS Letters, 1991
- Molecular cloning and expression of an IL-6 signal transducer, gp130Cell, 1990
- Microtubular reorganization and dendritic growth response in alzheimer's diseaseAnnals of Neurology, 1989
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- Estimation of Error Rates in Discriminant AnalysisTechnometrics, 1968